• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    • Overview
    • Buy Sell Zone
    • F&O
    • Financials
    • News
      All News Earnings Calls Corporate Announcements Research Reports
    • Reports
    • Technicals
      Technicals Share Price History Delivery
    • Shareholding
      Shareholding Monthly MF Holdings Bulk Block Deals Insider Trading & SAST
    • Deals
      Bulk Block Deals Insider Trading & SAST
    • Corporate Actions
      All Dividend Bonus Split Rights Board Meetings
    • Alerts
    • About

    Aurobindo Pharma Ltd.

    NSE: AUROPHARMA | BSE: 524804 | ISIN: INE406A01037 | Industry: Pharmaceuticals
    US FDA Observation High Gain High Volume
    | Mid-range Performer
    1109.2000 58.90 (5.61%)
    NSE Sep 11, 2025 15:31 PM
    30.33% Fall from 52W High
    Volume: 5.9M
    High volume+gain today
    • Share on Facebook
    • Tweet
    • Share on LinkedIn
    • Share via Whatsapp

    logo
    Aurobindo Pharma Ltd.
    27 Dec 2023
    US FDA Observation High Gain High Volume
    1109.20
    5.61%
    AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
    BSE India
    Press release in connection with USFDA approval received by Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company.
    pdf
    Copy Link Share on Share on Share on Share on
    Alert
    More from Aurobindo Pharma Ltd.
    Recommended
    Market closes higher, Tega Industries to buy Molycop with Apollo Funds in a $1.5 bn deal
    Trendlyne Marketwatch | 11 Sep 2025, 04:07PM
    India’s IPO story in 2025: Investors go selective, backing quality over hype
    The Baseline | 11 Sep 2025, 03:50PM
    A deal is called off, increasing the chance for Aurobindo Pharma to be debt free
    | 15 Jul 2020
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd